Cellular prion protein (PrP C ) is widely expressed and displays
a variety of well-described functions in the central nervous system (CNS). Mutations of the PRNP gene are known to promote genetic human spongiform encephalopathies, but the components of gain-or loss-of-function mutations to PrP C remain a matter for debate. Among the proteins described to interact with PrP C is Stress-inducible protein 1 (STI1), a cochaperonin that is secreted from astrocytes and triggers neuroprotection and neuritogenesis through its interaction with PrP C . In this work, we evaluated the impact of different PrP C pathogenic point mutations on signaling pathways induced by the STI1-PrP C interaction. We found that some of the pathogenic mutations evaluated herein induce partial or total disruption of neuritogenesis and neuroprotection mediated by mitogen-activated protein kinase (MAPK)/extracellular signalregulated kinases 1 and 2 (ERK1/2) and protein kinase A (PKA) signaling triggered by STI1-PrP C engagement. A pathogenic mutant PrP C that lacked both neuroprotection and neuritogenesis activities fail to promote negative dominance upon wild-type PrP C . Also, a STI1-a7-nicotinic acetylcholine receptor-dependent cellular signaling was present in a PrP C mutant that maintained both neuroprotection and neuritogenesis activities similar to what has been previously observed by wild-type PrP C . These results point to a loss-offunction mechanism underlying the pathogenicity of PrP Prion diseases are fatal disorders of both humans and animals and can be acquired, spontaneous or genetic in origin (Prusiner and Scott 1997) . The genetic human spongiform encephalopathies, including Creutzfeldt-Jakob Disease, Fatal Familial Insomnia, and Gerstmann-Straussler-Scheinker disease, are among the maladies that have been associated with about 44 point mutations and 10 insertions/deletions within the PRNP gene, which encodes PrP C . The incidence of these mutations as well as associated clinical features is broad and variable (Prusiner and Scott 1997; Minikel et al. 2016; Takada et al. 2017) . In the last decade, a wide range of functions has been attributed to native PrP C protein, such as neuroprotection against cellular (Chiarini et al. 2002; Zanata et al. 2002; Roucou et al. 2003; Lopes et al. 2005; Bounhar et al. 2001) and systemic (McLennan et al. 2004; Weise et al. 2004 Weise et al. , 2006 Shyu et al. 2005) insults, neuritogenesis (Lopes et al. 2005) , neuronal plasticity (Amin et al. 2016) and memory formation and consolidation (Coitinho et al. 2006 (Coitinho et al. , 2007 . Multiple ligands and signaling pathways have also been associated with PrP C functions (Linden et al. 2018) , and PrP C has been proposed to drive the association of multicomponent complexes at the cell surface (Linden et al. 2008) and to organize a dynamic cell surface platform for the assembly of signaling modules (Linden et al. 2008) . Regarding the important physiological properties of PrP C , the roles for both gain-and loss-of-function mutations in , cellular prion protein; CJD, CreutzfeldtJakob Disease; FFI, fatal familial insomnia; GSS, Gerstmann-Straussler-Scheinker disease; STI1, Stress-inducible protein 1; DAPI 4 0 -6-diamidino-2-phenylindole; MAPK/ERK1/2, mitogen-activated protein kinase; PKA, protein Kinase A; KT5720, PKA inhibitor; U0126, MAPK/ERK1/2 (p44/p42 MAPK) inhibitor 1,4-diamino-2, 3-dicyano-1,4-bis (2-aminophenylthio) butadiene.
promoting disease remain debatable (Hetz et al. 2003; Leighton and Allison 2016; Minikel et al. 2016; Guerrero et al. 2017) . Our group showed that PrP C point mutations impair PrP C -laminin dependent signaling pathways (Machado et al. 2012) , contributing to the identification of cellular mechanisms associated with loss of PrP C function. Among the other PrP C ligands, Stress-inducible protein 1 (STI1), first described as a component of the Hsp70 and Hsp 90 chaperone family of proteins (L€ assle et al. 1997; BaindurHudson et al. 2015) , is also known to be secreted by astrocytes (Lima et al. 2007) at the surface of extracellular vesicles (Hajj et al. 2013) . Its binding to PrP C induces activation of PKA and ERK1/2, promoting neuroprotection and neuritogenesis, respectively (Chiarini et al. 2002; Zanata et al. 2002; Lopes et al. 2005 
Materials and methods

Peptides and chemicals
Mouse recombinant STI1 (His 6 -STI1) and a STI1 deletion mutant lacking the PrP C binding site (STI1 Δ230-245 ) were purified as previously described . The mitogen-activated protein kinase MAPK/ERK1/2 (p44/p42 MAPK) inhibitor 1,4-diamino-2,3-dicyano-1,4-bis (2-aminophenylthio) butadiene (U0126) was purchased from Promega (Madison, WI, USA). The PKA inhibitor KT5720 and 4 0 -6-diamidino-2-phenylindole (DAPI)
were purchased from Calbiochem (La Jolla, CA, USA) and a-bungarotoxin (ab120542) was from Abcam (Cambridge, UK ERK1/2 activity 10 5 CF10 cells (transfected or non-transfected) were plated on dishes and stimulated with 500 nM STI1 for 1 min. Some cells were also pre-incubated with 10 lM U0126 for 1 h prior to STI1 treatment. Western blotting analyses were performed as previously described (Machado et al. 2012) , with results represented three independent experiments.
Process outgrowth assays 10 5 CF10 cells (transfected or non-transfected) were treated with 500 nM STI1 and incubated for 48 h at 37°C. Process outgrowth mediated by STI1 was evaluated after pre-incubation with 10 lM U0126 or 60 nM KT5720 for 1 h. Cells treated with STI1 Δ230-245 were used as a control. Cells were fixed with 4% paraformaldehyde and 0.12 M sucrose in phosphate-buffered saline (PBS), pH 7.4, for 20 min at 22°C, then washed three times with PBS and stained with hematoxylin. Morphometric analyses were performed using ImageJ software (National Institutes of Health) and the Neuron J plugin. Approximately 200 cells were analyzed per sample.
Cell death assay 10 5 CF10 cells (transfected or non-transfected) were treated with 500 nM STI1 for 1 h, followed by 10 lM staurosporine treatment for 16 h, as previously described (9). Alternatively, 10 lM U0126 or 60 nM KT5720 was added to the cultures 1 h prior to incubation with STI1. Cells were then fixed with 4% paraformaldehyde and 0.12 M sucrose in PBS, pH 7.4, for 20 min. Immunofluorescence reactions were performed to detect cleaved caspase 3. Briefly, cells were permeabilized and blocked with PBS/0.2% Triton X-100 containing 5% bovine serum albumin (BSA) for 1 h and subsequently incubated with anti-cleaved caspase 3 primary antibody (1 : 200) diluted in PBS/0.2% Triton X-100 plus 1% BSA for 2 h. After rinsing with PBS, cells were incubated with Alexa Fluor 488 anti-rabbit antibody and DAPI for 1 h. Immunolabeled cells were imaged with a Nikon TE2000U microscope. Cell death induced by staurosporine was represented by the percentage of cleaved caspase 3 positive cells. Results represent three independent experiments; at least 200 cells were counted per condition.
Generation of double transfected cells
PrP3F4 cells were transfected with the PrP C mutant PrP199K using Lipofectamine 2000 (Invitrogen, Carlsbad, CA, USA) as previously described (Machado et al. 2012) . After 48 h of transfection, cells were treated with STI1 500 nM for 1 min and ERK1/2 activity was measured as described above. Results represent four independent experiments.
Flow cytometry analysis and a-bungarotoxin effect upon ERK1/2 activation triggered by STI1-PrP C interaction
To analyze a-7 nicotinic acetylcholine receptor (a7nAChR) expression on the plasma membrane, cells (CF10, PrP3F4, PrP101L, PrP104L, PrP116V, PrP177N, PrP179I, and PrP199K) were incubated with blocking solution (0.5% BSA in PBS) plus anti-a7nAChR antibodies (1 : 100) incubated for 1 h at 4°C, washed, and followed by anti-Rabbit IgG conjugated to Alexa Fluor 488 (1 : 500) for 1 h at 4°C. Analyses were performed using a FACSCalibur flow cytometer (BD Biosciences, San Jose, CA, USA), and data acquired from 10 000 events were analyzed using FloJo â (BD Biosciences, San Jose, CA, USA). Analysis was performed gating on live cells based on side scatter (SSC) versus forward scatter, as determined by propidium iodide exclusion based. Negative controls of the secondary antibody (Rabbit IgG conjugated to Alexa Fluor 488) alone were included in all staining reactions. CF10 and PrP177N mutants were treated or not with 1 nM a-bungarotoxin for 30 min and then STI1 500 nM was added for 1 min at 37°C. The phosphorylation of ERK1/2 was measured as described above. Results represent three independent experiments.
Statistical analysis
Statistical analyses were performed using GraphPad Prism 5 (RRID: SCR_015807; GraphPad, San Diego, CA, USA). Results are shown as the means AE SE, and the number of experiments performed in each condition is stated in the respective figure legend. Data were compared by one-way analyses of variance and Dunnett's post-test. Differences were considered significant at p ≤ 0.05.
Results and discussion
In this study, we used PrP C -knockout mouse CF10 cells expressing wild-type PrP3F4 or PrP101L, PrP104L, PrP116V, PrP177N, PrP179I, and PrP199K mutant forms of mouse PrP C generated previously (Machado et al. 2012 ). These mutations correspond, respectively, to disease-associated human mutations at amino acids 102, 105, 117 (related to Gerstmann-Straussler-Scheinker disease), 178 fatal familial insomnia, 180 and 200 Creutzfeldt-Jakob Disease (Machado et al. 2012) and were addressed to investigate the effects of various point mutations on PrP C signaling triggered by STI1. All transfected PrP C proteins carried a methionine at amino acid 128 (corresponding to the codon 129 at the human protein). Results showed that knockout cells, as well as cells expressing mutant forms of PrP C , presented higher levels of basal ERK1/2 phosphorylation when compared with cells expressing PrP3F4 (Fig. 1a and  b) . This result is consistent with a previous report from our group showing that PrP C -knockout hippocampal neurons displayed higher basal ERK1/2 phosphorylation when compared with wild-type neurons (Lopes et al. 2005) . Cells were then treated with 500 nM STI1 for 1 min. ERK1/2 phosphorylation increased about 12-fold in cells expressing PrP3F4, whereas no ERK1/2 activation was seen in knockout cells or in cells expressing PrP C mutants PrP101L, PrP104L, and PrP199K (Fig. 1a and c) . After STI1 treatment, ERK1/2 phosphorylation increased nearly 3-fold in PrP116V, PrP177N, and PrP179I mutant cells (Fig. 1a and c) . This level of phosphorylation is significantly lower than that induced by STI1 in CF10 cells expressing wild-type PrP3F4 (Fig. 1c) . Since the ERK1/2 signaling triggered by the STI1-PrP C interaction is known to promote neurite outgrowth (Lopes et al. 2005) , we further investigated the process in PrP C -mutant cells. As observed for ERK1/2 phosphorylation, only PrP3F4 and mutants PrP116V and PrP177N displayed a higher number of cells with processes when treated with STI1 as compared with respective nontreated controls (Fig. 1d) . Furthermore, a significantly increased number of PrP3F4 CF10 cells with processes was observed after stimulation with STI1 than when same treatment was performed PrP116V and PrP177N CF10 mutants. Conversely, no increase in the number of cells with processes was observed in PrP179I mutants, despite a STI1-mediated increase in ERK1/2 phosphorylation (Fig. 1d) . To confirm whether the stimulation of neurite outgrowth triggered by STI1 was specifically dependent on ERK1/2 signaling, cells were pre-treated with the ERK1/2 inhibitor U0126 or with the PKA inhibitor KT5720, as a control. For these experiments, only PrP3F4 CF10 cells, knockout cells and cells expressing the PrP116V and PrP177N mutants (which show ERK1/2 induction and neuritogenesis upon STI1 treatment) were used. The STI1 molecule lacking the PrP C binding site (STI1 Δ230-245 ) had no effect on neurite outgrowth, indicating that STI1 interaction with PrP C is required for this process (Fig 1e) . In addition, neurite outgrowth in cells expressing PrP3F4, PrP116V, and PrP177N was completely abolished by the ERK1/2 inhibitor (U0126) but not by the PKA inhibitor (KT5720). Thus, neuritogenesis mediated by STI1 in the latter cells is dependent on ERK1/2 signaling (Fig. 1e) .
Because interaction of PrP C with STI1 also protects against cell death (Lopes et al. 2005) , we further evaluated if PrP C mutants could lose their protective properties. PrP3F4 CF10 cells were protected from death promoted by staurosporine once treated with STI1, whereas treatment with STI1 Δ230-245 had no neuroprotective effect (Fig. 2a) , indicating the importance of STI1-PrP C binding for this effect. STI1 had no protective effect on PrP C -knockout cells (Fig. 2a) . The same was observed for most cells expressing mutant PrP C , except for PrP101L and PrP177N cells, in which STI1 promoted neuroprotection (Fig. 2a) . This effect was less prominent in PrP177N cells than in PrP3F4 or PrP101L cells (Fig. 2a) . We next investigated whether the neuroprotective effect of STI1 in these cells was mediated by PKA activation, as previously demonstrated (Lopes et al. 2005) . Results showed that PKA inhibitor KT5720, but not ERK1/2 inhibitor U0126, blocked the neuroprotective effect induced by STI1 (Fig. 2b) . These findings indicate that neuritogenesis is mediated by PKA signaling, in turn triggered by STI1 binding to PrP C (Fig. 2b) . To investigate if the mutants lacking STI1 activity were able to display a dominant negative effect upon wild-type PrP C , PrP3F4 cells were transient transfected with the mutant PrP199K that lacks both neuritogenesis and neuroprotection activities. Fig. 3a shows an increase in PrP C expression in transfected cells indicating that the mutant protein had been expressed. After treatment with STI1 the levels of ERK1/2 phosphorylation increased in cells expressing both the wildtype protein and the mutant PrP199K (Fig. 3b) . Thus, pointing that this mutant was unable to repress the activity of the wild-type PrP C and indeed it did not present dominant negative properties.
We previously demonstrated that ERK1/2 phosphorylation promoted by STI1-PrP C interaction is mediated by a complex formed between these proteins and the a7nAChR (Beraldo et al. 2010). Flow cytometry experiments indicated that cells studied here (CF10, PrP3F4, PrP101L, PrP104L, PrP116V, PrP177N, PrP179I, and PrP199K) expressed this receptor at the cell membrane (Fig. 4a) . All cell line express a7nAChR to the range between 3.52-0.43%, and there was no correlation between failure to respond and expression levels of a7nAChR. In addition, cells expressing PrP177N that were able to respond to STI1 treatment inducing neuritogenesis and survival showed an ERK1/2 phosphorylation impairment after STI1 treatment in the presence of a-bungarotoxin, an a7nAChR inhibitor (Fig. 4b ). This result indicates that, similar to the wild-type PrP C , PrP C mutants that respond to STI1 stimulation also organize complexes with a7nAChR.
In a previous publication, our group showed that ERK1/2 signaling triggered by the PrP C -STI1 interaction depends on the endocytosis of PrP C (Caetano et al. 2008) , and also that this interaction is transient once both molecules are internalized (Caetano et al. 2008) . PKA activation is not otherwise dependent on that process (Caetano et al. 2008 ). The differential mechanisms by which STI1 triggers activation of ERK1/2 and PKA pathways after interacting with PrP C may help to explain the variable responses observed across CF10 cells expressing PrP C mutations associated with genetic prion disease.
Among the different types of prion mutations described in the literature, point mutations linked to human genetic prion diseases are generally thought to display PrP Sc -like biochemical properties. The resulting proteins are prone to the formation of oligomeric aggregates, which is said to promote their pathogenicity. Importantly, no infectious PrP Sc formation was observed for the mutants studied here (Solomon et al. 2001) . In our previous work (Machado et al. 2012) , we showed that only PrP104L and PrP179I PrP C mutants displayed subtle increases in resistance to digestion with proteinase K. Interestingly, in the present work, cells expressing the PrP104L mutant showed no response to STI1 treatment in the evaluated phenotypes. Cells expressing the PrP179I mutant displayed an increase in ERK1/2 phosphorylation, whereas no corresponding increase in the number of cell processes was observed.
Moreover, others have reported that human mutant PrP C variants P102L, P105L, and A117V, which correspond to PrP101L, PrP104L, and PrP116V in the present work, have an enhanced affinity for cellular membranes (Hornemann et al. 2009 ). The authors suggested that this could promote the gain or loss of PrP C function, ultimately affecting the physiological roles of PrP C in health and in prion disease (Hornemann et al. 2009 ). Our results showed that these mutations were able to promote partial (e.g., PrP101L and PrP116V mutations) or total (e.g., PrP104L mutant) loss of the physiological response induced by STI1.
Indeed, Mansouri and coworkers (Mansouri et al. 2013 ) reported that the p.D178N mutation, which corresponds to PrP177N in this work, promotes structural changes in the mutated protein, ultimately causing intermolecular interactions and conformational rearrangements. The reason may be the reduction in electrostatic forces caused by the absence of Asp's negative charge. Interestingly, our results showed that only CF10 cells expressing PrP177N displayed both neuritogenesis and neuroprotection dependent on STI1. The magnitude of this response was also lower when compared with that of PrP3F4 CF10 cells. Furthermore, the pathogenic mutation p.E200K, corresponding to the present PrP199K, perturbed the a3 electronegative surface, leading to structural and metabolic traits (Mart ınez et al. 2015; Wang et al. 2016) , as observed with PrP104L, which showed no response to STI1 treatment. A previous report showed that the interaction between PrP C and STI1 alters the structure of both components (Romano et al. 2009 ). These structural changes in either PrP C or STI1 upon binding may expose or hide putative binding sites for the assembly of higher order protein complexes at the cell surface (Romano et al. 2009) , as observed for the complex between PrP C -STI1 and the a7nAChR (Beraldo et al. 2010 ). Once we showed that all cell types evaluated here express a7nAChR, the lack of STI1-mediated survival and differentiation in cells expressing PrP104L and PrP199K suggested impairment in the interaction of these mutated proteins with the a7nAChR.
Our previous work demonstrated that all PrP C -mutated molecules studied here impaired Ca 2+ and PKC signaling and were unable to activate neuritogenesis or survival through laminin interaction (Machado et al. 2012) . These results are partially in conflict with the present results, in which 2 of the PrP C mutants showed activity only in neuritogenesis (PrP116V) or survival (PrP101L) and one mutation activated both phenotypes (PrP177N). However, they could represent higher order of PrP C organization of signaling platforms, which in the case of PrP C -STI1 is mediated by a7nAChR (Beraldo et al. 2010) and for laminin by metabotropic glutamate receptor (mGluR) (Beraldo et al. 2011) .
Results from the literature together with those prescribed here indicate that different point mutations in the PrP C protein may compromise the structural rearrangements not only between PrP C and specific ligands but also throughout multiprotein complexes organized in signaling platforms that modulate diverse cellular phenotypes. The data presented here support a loss of physiological functions associated with PrP C point mutations related to the inherited forms of human prion diseases.
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